Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blephagiene
- Development stage
- Unknown
- Lead developer
- Aurolab
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Blephagiene is a topical eyelid cleanser formulated as a pre-lathered foam for daily eyelid and lash hygiene. Developed by Aurolab and distributed by Brady Pharma, it is designed to clear debris, oil buildup, and crusts from the eyelid margins, helping to manage blepharitis, dry eye symptoms, and maintain overall ocular surface health. The formulation contains cetrimide (an antiseptic and cationic surfactant) along with electrolytes including sodium chloride, potassium chloride, and calcium chloride to soothe and cleanse the eyelids without irritation.
- Brand names
- Blephagiene
- Other names
- Blephagiene Eyelid Cleansercetrimide + sodium chloride + potassium chloride + calcium chloride
Beyond the preview
Go deeper on Blephagiene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blephagiene.